Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Department of Drug Development and Innovation (D3i), Institut Curie, Saint-Cloud, France.
J Gynecol Oncol. 2023 Sep;34(5):e74. doi: 10.3802/jgo.2023.34.e74.
Loss of function in epigenetic acting genes together with driver alterations in the PIK3CA pathway have been shown significantly associated with poor outcome in cervical squamous cell cancer. More recently, a CoxBoost analysis identified 16 gene alterations and 30 high level activated proteins to be of high interest, due to their association with either good or bad outcome, in the context of treatment received by chemoradiation. The objectives here were to review and confirm the significance of these molecular alterations as suggested by literature reports and to pinpoint alternate treatments options for poor-responders to chemoradiation.
表观遗传作用基因的功能丧失，以及 PIK3CA 通路中的驱动因素改变，已被证明与宫颈鳞癌的不良预后显著相关。最近，CoxBoost 分析确定了 16 个基因改变和 30 个高水平激活的蛋白质，由于它们与接受放化疗的患者的良好或不良预后相关，因此具有很高的研究价值。本研究旨在通过文献报道，对这些分子改变的意义进行综述和确认，并为放化疗反应不佳的患者寻找替代治疗方案。
